AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Sunday 1 November 2026
News from the 24 hours to Sunday morning, 1 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on third-quarter results showing profit growth and an unchanged outlook, alongside a new cost-saving programme to fund the drug pipeline. A new lung cancer drug launch in the US and a lift to the FTSE 100 added to the positive lean, with some caution over valuation.
What drove it
- Q3 results
- savings programme
- US drug launch
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Mon 26 Oct | +10.0 | 33 |
| Tue 27 Oct | +9.2 | 35 |
| Wed 28 Oct | +7.5 | 33 |
| Thu 29 Oct | +2.8 | 13 |
| Fri 30 Oct | +6.3 | 13 |
| Sat 31 Oct | +8.7 | 78 |
| Sun 1 Nov | +6.3 | 8 |
3 stories · 8 headlines · strongest first
Pharma and healthcare on 1 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca Q3 results and $1.5bn savings plan +6.86 headlines today · 65 in all, since 31 October · Outlets cover AstraZeneca's Q3 results, unchanged 2026 outlook, $1.5bn savings drive, call transcript and valuation. | ||
| +7.3 | Third-quarter growth leaves full-year guidance unchanged, reassuring for investors. | |
| +7.0 | Quarterly results showing profit expansion, though valuation concerns temper enthusiasm. | |
| +5.5 | Efficiency drive to free money for research and development. | |
| +5.2 | Forward-looking coverage of growth prospects and pipeline plans for coming years. | |
| +4.5 | Cost-cutting programme linked to its long-term revenue ambition. | |
| +2.0 | Transcript of management's quarterly call; factual record with little new information. | |
| AstraZeneca launches lung cancer drug in US +8.51 headline today · AstraZeneca has introduced a targeted treatment for lung cancer in the US. | ||
| +8.5 | New targeted oncology medicine reaching the American market. | |
| FTSE 100 rises on AstraZeneca +8.31 headline today · 16 in all, since 31 October · The FTSE 100 climbed to 10,729.78, with gains in AstraZeneca and BT outweighing a decline in NatWest. | ||
| +6.3 | Shares helped lift the FTSE 100 on the day. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.